GlobeNewsWire
08 Jun 2026, 05:00 UTC · 9h ago
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
GlobeNewsWire
08 Jun 2026, 05:00 UTC · 9h ago
Story key points
4 claims · impact-rated
Nurix Therapeutics will receive an upfront cash payment of $700 million and potential milestone payments totaling up to $2.3 billion from Roche. — Substantial non-dilutive capital infusion and a high-value validation of Nurix's lead asset provide a significant immediate catalyst for NRIX share price.
+0.80Bexobrutideg (NX-5948) is scheduled to initiate Phase 3 clinical trials in summer 2026 for the second-line treatment of CLL. — Moving into Phase 3 represents a critical derisking step toward commercialization in a market projected to reach $16 billion by 2035.
+0.60Roche and Nurix will co-develop and co-commercialize bexobrutideg across malignant haematology, immunology, and neurology. — Expanding the therapeutic reach into immunology and neurology increases the total addressable market beyond the core oncology focus.
+0.50Continue reading
6 related stories
Top 2 movers · tap to explore
Roche will cover 60% of development costs and share U.S. profits and losses equally with Nurix. — Shifting the majority of R&D expenses to Roche significantly reduces the financial burn and risk for the smaller partner, Nurix.
+0.40Ticker attribution
Model heads
Nurix receives a $700 million upfront payment and potential deal value of up to $2.3 billion through a major collaboration with Roche.
Roche expands its pipeline in haematology, immunology, and neurology through a strategic collaboration to develop a potentially best-in-class drug.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
9 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
